marginal zone B and B1 cell specific proteinGenealiases: MEDA-7 · PACAP · pERp1
Q-omics provides the consensus-scored MZB1 profile across patient tissues and cancer cell-line models. MZB1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MZB1 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, MZB1 protein abundance shows 18,523 significant gene co-expression associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where MZB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MZB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MZB1 survival associations across molecular data types. MZB1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MZB1 RNA expression–survival associations across cancer types. High MZB1 expression shows unfavorable associations in KIRC, but favorable associations in HNSC, SKCM, BRCA, CESC and OV. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MZB1 RNA expression.
This table summarizes MZB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MZB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MZB1 shows lower tumor expression in COAD, READ, KICH and LIHC and higher tumor expression in LUAD and KIRC. The COAD box plot shows higher MZB1 RNA expression in normal versus tumor tissue (log2 FC = −3.258, t-test p < 0.001).
This table shows molecular features associated with MZB1 in patient tissues and cancer cell lines. In patient samples, MZB1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MZB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
